Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurosurgery

Surgical Management and Controlling Symptoms

At a Glance

For diffuse leptomeningeal melanocytosis, a brain shunt or temporary drain can relieve dangerous fluid pressure and improve headaches, vomiting, and sleepiness. Seizure medicines are individualized, and families need an urgent action plan for shunt problems or prolonged seizures.

While there is currently no universal “cure” for Diffuse Leptomeningeal Melanocytosis (DLM) or Neurocutaneous Melanosis (NCM), medical and surgical management focuses heavily on two critical areas: relieving the pressure caused by fluid buildup and controlling seizures [1][2].

The goal of these treatments is to improve quality of life and protect the brain from damage caused by high pressure. It is important to understand that while these interventions are often life-saving and provide significant symptom relief, they are “supportive” measures—they manage the effects of the condition rather than stopping the growth of the pigment cells themselves [3][4].

Managing Brain Pressure: Shunts and Drains

In specific published patient groups, elevated intracranial pressure or hydrocephalus has been observed in 24% to 67% of cases [1][5]. This leads to hydrocephalus, a condition where fluid builds up and creates dangerous pressure inside the skull.

To manage clinically significant hydrocephalus, neurosurgeons use “diversion” techniques to move the fluid to another part of the body.

  • Ventriculoperitoneal (VP) Shunt: This is a common long-term solution [1]. A thin, flexible tube is surgically placed into the ventricles (fluid-filled spaces) of the brain. The tube runs under the skin down to the abdomen (peritoneum), where the excess fluid is safely absorbed [6]. It drains fluid based on fixed or programmable valve settings.
  • External Ventricular Drain (EVD): This is typically a temporary measure used in emergency situations or during a hospital stay [6]. A tube is placed in the brain and connected to a collection bag outside the body [7].

What to Expect After Shunting

A successful shunt can lead to a dramatic improvement in symptoms like headaches, vomiting, and extreme sleepiness [2][8]. However, shunts in DLM patients face unique challenges:

  1. Protein and Cell Clogging: The CSF in people with DLM often contains very high levels of protein and sometimes floating pigment cells [9]. These can clog the small valves or tubes, leading to a “shunt malfunction” [10]. In one published cohort, approximately 43% of patients with a shunt eventually required a shunt revision (a second surgery to fix a blocked part) [11].
  2. Valve Settings and Complications: Families need to know about infection risks, blockage, under-drainage, over-drainage (which can cause headaches or bleeding), and the need for urgent assessment if symptoms recur.
  3. Rare Risks: Extracranial spread of the disease down the shunt tubing to the abdomen is a very rare observation reported in individual case studies, not a routinely expected outcome [12]. If symptoms return after shunting, doctors will usually first evaluate for malfunction, infection, or standard disease progression rather than automatically assuming malignant transformation [13].

Controlling Seizures

Seizures are a common complication, occurring in roughly 55% of reported cases [1]. They happen because the pigment cells irritate the outer surface of the brain [14].

  • Emergency (Acute) Management: If a prolonged seizure occurs, the priority is to stop it using specific rescue plans (often involving benzodiazepines) [15][16]. Status epilepticus is a medical emergency [17].
  • Daily Prevention (Prophylaxis): Preventative antiseizure medications are highly individualized based on seizure type, age, and comorbidities [18]. While levetiracetam is sometimes used, it can cause somnolence, irritability, or mood and behavioral changes, especially in children [19]. Medication choices are tailored, and prophylaxis is not automatically indicated for every seizure-free patient.
  • Monitoring and Adjustment: Doctors use EEG (a test that measures brain waves) to support clinical decisions. A normal EEG does not completely rule out seizures, and an abnormal EEG is interpreted alongside actual clinical symptoms [20][21].

Managing these symptoms requires constant communication with your neurosurgical and neurology team to ensure that any sign of shunt failure or new seizure activity is caught and treated as quickly as possible [22].

Common questions in this guide

Why might a person with diffuse leptomeningeal melanocytosis need a VP shunt?
A VP shunt moves excess cerebrospinal fluid from the brain’s ventricles to the abdomen when hydrocephalus causes dangerous pressure. It can improve headaches, vomiting, and severe sleepiness, but it treats the fluid buildup rather than the underlying pigment-cell growth.
What symptoms may mean that a shunt is blocked or not working?
Return or worsening of headaches, vomiting, unusual sleepiness, or other symptoms that improved after shunting can signal a problem. Infection, blockage, under-drainage, or over-drainage are possible, so new or recurring symptoms need urgent assessment by the neurosurgical team rather than being assumed to be disease progression.
Does high protein in spinal fluid increase the risk of shunt blockage?
Yes. High protein and floating pigment cells in cerebrospinal fluid can clog the tubing or valve, and some people need a shunt revision to restore drainage. Doctors monitor symptoms and shunt function over time.
How are seizures managed in diffuse leptomeningeal melanocytosis?
A prolonged seizure needs an emergency rescue plan, often including a benzodiazepine, because status epilepticus is a medical emergency. Daily antiseizure medicine may help prevent seizures, but the choice depends on seizure type, age, and other health factors.
Does a seizure-free child still need daily antiseizure medicine?
Not automatically. The neurology team weighs the seizure history, EEG findings, age, other health conditions, and medication risks before deciding whether to start, continue, or reassess preventive treatment.
What role does an EEG play in seizure care?
An EEG is a test that measures brain-wave activity and can support decisions about seizure treatment. A normal EEG does not completely rule out seizures, and an abnormal result must be considered alongside what happened clinically.

Get notified when new evidence is published on Diffuse leptomeningeal melanocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Neurosurgical management of patients with neurocutaneous melanosis: a systematic review.

    Rahman RK, Majmundar N, Ghani H, et al.

    Neurosurgical focus 2022; (52(5)):E8 doi:10.3171/2022.2.FOCUS21791.

    PMID: 35535823
  2. 2

    Shunt Surgery for Neurocutaneous Melanosis with Hydrocephalus: Case Report and Review of the Literature.

    Omar AT, Bagnas MAC, Del Rosario-Blasco KAR, et al.

    World neurosurgery 2018; (120()):583-589.e3 doi:10.1016/j.wneu.2018.09.002.

    PMID: 30205217
  3. 3

    Neurocutaneous melanosis presenting with hydrocephalus and malignant transformation: case-based update.

    Sharouf F, Zaben M, Lammie A, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2018; (34(8)):1471-1477 doi:10.1007/s00381-018-3851-5.

    PMID: 29948137
  4. 4

    Neurocutaneous Melanosis with Meningeal Melanocytosis: A Rare Case of Intracranial Hypertension and Cutaneous Manifestations.

    Chen HC, Hsu TI, Chao TY, Yang ST

    Life (Basel, Switzerland) 2024; (14(1)) doi:10.3390/life14010139.

    PMID: 38255754
  5. 5

    Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis.

    Baumgartner A, Stepien N, Mayr L, et al.

    Journal of personalized medicine 2021; (11(4)) doi:10.3390/jpm11040292.

    PMID: 33921303
  6. 6

    Primary Diffuse Leptomeningeal Melanomatosis in an Indian Child With Review of Literature.

    Kumar A, Gunasekaran PK, Aggarwal D, et al.

    Pediatric neurology 2024; (152()):23-29 doi:10.1016/j.pediatrneurol.2023.12.007.

    PMID: 38176225
  7. 7

    External ventricular drainage in pediatric patients: indications, management, and shunt conversion rates.

    Atallah O, Krauss JK, Hermann EJ

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(7)):2071-2079 doi:10.1007/s00381-024-06367-y.

    PMID: 38557894
  8. 8

    Diffuse leptomeningeal glioneuronal tumour: where to biopsy? Case report and literature review.

    Sáez-Alegre M, Saceda Gutiérrez JM, Utrilla Contreras C, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2021; (37(7)):2405-2408 doi:10.1007/s00381-020-04955-2.

    PMID: 33128604
  9. 9

    Aggressive Diffuse Leptomeningeal Glioneuronal Tumor in a Pediatric Patient Presenting With Mismatch Repair Gene Mutations.

    Torres-Rey A, Vigo-Prieto J, De Jesus O

    Cureus 2023; (15(10)):e47905 doi:10.7759/cureus.47905.

    PMID: 38034149
  10. 10

    Improvised external ventricular drain in neurosurgery: A Nigerian tertiary hospital experience.

    Ojo OA, Asha MA, Bankole OB, Kanu OO

    Journal of neurosciences in rural practice 2015; (6(3)):304-8 doi:10.4103/0976-3147.158743.

    PMID: 26167009
  11. 11

    Disseminated pediatric low-grade glioma and hydrocephalus: a multinational consortium analysis of incidence and mortality.

    Lyons AT, Haizel-Cobbina J, Levine A, et al.

    Journal of neurosurgery. Pediatrics 2025; (37(2)):133-146 doi:10.3171/2025.8.PEDS25160.

    PMID: 41569919
  12. 12

    Neurocutaneous melanocytosis-associated malignant melanoma presenting with peritoneal seeding.

    Sener U, Elmore K, Jayaseelan K, et al.

    Pediatric dermatology 2021; (38(5)):1298-1301 doi:10.1111/pde.14789.

    PMID: 34463389
  13. 13

    Missense mutation of NRAS is associated with malignant progression in neurocutaneous melanosis.

    Takahashi H, Natsumeda M, Hara N, et al.

    Acta neuropathologica communications 2024; (12(1)):14 doi:10.1186/s40478-024-01723-0.

    PMID: 38254245
  14. 14

    Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases.

    Uguen A, Laurent C, Samaison L, et al.

    Human pathology 2015; (46(8)):1189-96.

    PMID: 26037215
  15. 15

    Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.

    Glauser T, Shinnar S, Gloss D, et al.

    Epilepsy currents 2016; (16(1)):48-61 doi:10.5698/1535-7597-16.1.48.

    PMID: 26900382
  16. 16

    Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial.

    Vignesh V, Rameshkumar R, Mahadevan S

    Indian pediatrics 2020; (57(3)):222-227.

    PMID: 32198861
  17. 17

    Diagnostic challenges of primary diffuse leptomeningeal melanomatosis in early adolescence: A case report.

    Yamauhci S, Fukuyama T, Inaba Y, et al.

    Brain & development 2022; (44(6)):421-425 doi:10.1016/j.braindev.2022.02.004.

    PMID: 35260265
  18. 18

    Guidelines for Seizure Prophylaxis in Patients Undergoing Supratentorial Neurosurgery: A Statement for Healthcare Professionals from the Neurocritical Care Society.

    Rowe AS, Ullman J, Johnson EL, et al.

    Neurocritical care 2026; (45(1)):34-57 doi:10.1007/s12028-026-02522-2.

    PMID: 42087034
  19. 19

    [Acute symptomatic epileptic seizures. A clinical-electroencephalographic etiological description and prognosis of an oncopediatric series].

    Ivarola P, González B, Tedeschini I, et al.

    Revista de neurologia 2024; (78(4)):93-99 doi:10.33588/rn.7804.2023260.

    PMID: 38349317
  20. 20

    Status epilepticus in the ICU.

    Rossetti AO, Claassen J, Gaspard N

    Intensive care medicine 2024; (50(1)):1-16 doi:10.1007/s00134-023-07263-w.

    PMID: 38117319
  21. 21

    Pharmacotherapy for Pediatric Convulsive Status Epilepticus.

    Singh A, Stredny CM, Loddenkemper T

    CNS drugs 2020; (34(1)):47-63 doi:10.1007/s40263-019-00690-8.

    PMID: 31879852
  22. 22

    Pearls & Oy-sters: Primary Diffuse Leptomeningeal Melanocytosis: A Diagnostic Conundrum.

    Selvarajan JMP, Epari S, Sahu A, et al.

    Neurology 2023; (101(5)):e576-e580 doi:10.1212/WNL.0000000000207195.

    PMID: 36878703

This page explains shunts, drains, seizure treatment, and monitoring for diffuse leptomeningeal melanocytosis for education only and does not replace medical advice. Your neurosurgery and neurology team should guide decisions for you or your child, including emergency care.

Guide contents Diffuse leptomeningeal melanocytosis
Research & Literature
03 Diagnosis and the Biology of Pigment Cells 05 Systemic and Radiation Treatments